Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Comprehensive Analysis of PTEN in Primary Cutaneous Melanoma

K. Němejcová, P. Dundr, R. Jakša, M. Bártů, I. Stružinská, J. Hojný, N. Hájková, O. Kodet

. 2020 ; 66 (1) : 7-16.

Jazyk angličtina Země Česko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc21014126

Grantová podpora
NV16-30954A MZ0 CEP - Centrální evidence projektů

Phosphatase and tensin homologue (PTEN) is a tumour suppressor gene implicated in tumorigenesis of melanoma, with distinct cytoplasmic and nuclear functions. Cytoplasmic PTEN negatively regulates the PI3K/AKT/mTOR signalling pathway, while nuclear PTEN works as a tumour suppressor. Clinical data suggest that the loss of PTEN function in melanoma is associated with aggressive tumour behaviour. We performed a comprehensive analysis of PTEN in 112 primary cutaneous melanomas including immunohistochemical (IHC), fluorescent in situ hybridization (FISH), next-generation sequencing (NGS), and epigenetic analysis. The goal of our study was to: (a) correlate PTEN expression with selected clinico-pathological variables, and assess its prognostic significance; (b) correlate molecular aberrations with PTEN expression to consider the utility of immunohistochemical analysis of PTEN protein expression for screening PTEN genetic alterations; (c) review the literature and evaluate the PTEN expression level in melanoma with respect to possible therapeutic targeting. Our results showed that PTEN molecular alterations were present in 4/20 (20 %) cases with a loss of expression, 3/11 (27 %) cases with clonal-like expression, and 1/81 (1 %) cases with positive PTEN expression. No PTEN promoter methylation was found in any of the cases. Even though the value of our observation is limited by the low number of cases fully evaluated by IHC (112 cases), FISH (19 cases) and NGS (30 cases), our data suggest that IHC is not an appropriate method for the screening of PTEN genetic alterations. Our survival analysis suggests that patients with positive cytoplasmic PTEN expression show better disease-free survival (P < 0.05).

Bibliografie atd.

Literatura

000      
00000naa a2200000 a 4500
001      
bmc21014126
003      
CZ-PrNML
005      
20210528134156.0
007      
ta
008      
210504s2020 xr ad f 000 0|eng||
009      
AR
035    __
$a (PubMed)32512654
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xr
100    1_
$a Němejcová, Kristýna $7 xx0233214 $u Institute of Pathology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Czech Republic
245    10
$a Comprehensive Analysis of PTEN in Primary Cutaneous Melanoma / $c K. Němejcová, P. Dundr, R. Jakša, M. Bártů, I. Stružinská, J. Hojný, N. Hájková, O. Kodet
504    __
$a Literatura
520    9_
$a Phosphatase and tensin homologue (PTEN) is a tumour suppressor gene implicated in tumorigenesis of melanoma, with distinct cytoplasmic and nuclear functions. Cytoplasmic PTEN negatively regulates the PI3K/AKT/mTOR signalling pathway, while nuclear PTEN works as a tumour suppressor. Clinical data suggest that the loss of PTEN function in melanoma is associated with aggressive tumour behaviour. We performed a comprehensive analysis of PTEN in 112 primary cutaneous melanomas including immunohistochemical (IHC), fluorescent in situ hybridization (FISH), next-generation sequencing (NGS), and epigenetic analysis. The goal of our study was to: (a) correlate PTEN expression with selected clinico-pathological variables, and assess its prognostic significance; (b) correlate molecular aberrations with PTEN expression to consider the utility of immunohistochemical analysis of PTEN protein expression for screening PTEN genetic alterations; (c) review the literature and evaluate the PTEN expression level in melanoma with respect to possible therapeutic targeting. Our results showed that PTEN molecular alterations were present in 4/20 (20 %) cases with a loss of expression, 3/11 (27 %) cases with clonal-like expression, and 1/81 (1 %) cases with positive PTEN expression. No PTEN promoter methylation was found in any of the cases. Even though the value of our observation is limited by the low number of cases fully evaluated by IHC (112 cases), FISH (19 cases) and NGS (30 cases), our data suggest that IHC is not an appropriate method for the screening of PTEN genetic alterations. Our survival analysis suggests that patients with positive cytoplasmic PTEN expression show better disease-free survival (P < 0.05).
650    _2
$a lidé $7 D006801
650    _2
$a hybridizace in situ fluorescenční $7 D017404
650    12
$a melanom $x genetika $7 D008545
650    _2
$a fosfohydroláza PTEN $x genetika $7 D051059
650    12
$a nádory kůže $x genetika $7 D012878
655    _2
$a časopisecké články $7 D016428
700    1_
$a Dundr, Pavel, $d 1971- $7 xx0080436 $u Institute of Pathology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Czech Republic
700    1_
$a Jakša, Radek $7 xx026017301 $u Institute of Pathology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Czech Republic
700    1_
$a Bártů, Michaela $7 xx0233216 $u Institute of Pathology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Czech Republic
700    1_
$a Stružinská, Ivana. $7 xx0137560 $u Institute of Pathology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Czech Republic
700    1_
$a Hojný, Jan $7 xx0233403 $u Institute of Pathology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Czech Republic
700    1_
$a Hájková, Nikola $7 xx0233334 $u Institute of Pathology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Czech Republic
700    1_
$a Kodet, Ondřej, $d 1983- $7 xx0170115 $u Department of Dermatology and Venereology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Czech Republic; Institute of Anatomy, First Faculty of Medicine, Charles University, Czech Republic
773    0_
$w MED00011004 $t Folia biologica $x 0015-5500 $g Roč. 66, č. 1 (2020), s. 7-16
856    41
$u https://pubmed.ncbi.nlm.nih.gov/32512654 $y Pubmed
856    41
$u https://fb.cuni.cz/file/5916/fb2020a0002.pdf $y plný text volně přístupný
910    __
$a ABA008 $b A 970 $c 89 $y p $z 0
990    __
$a 20210504 $b ABA008
991    __
$a 20210520133717 $b ABA008
999    __
$a ok $b bmc $g 1657539 $s 1134514
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 66 $c 1 $d 7-16 $i 0015-5500 $m Folia biologica (Praha) $n Folia biol. (Praha) $x MED00011004
GRA    __
$a NV16-30954A $p MZ0
LZP    __
$b NLK118 $a Pubmed-20210504

Najít záznam

Citační ukazatele

Možnosti archivace